Biotech company Biogen lowered its full-year profit forecast, citing higher costs related to its purchase of drug maker Reata Pharmaceuticals as well as the launch of its Alzheimer's drug.

Share:
More In Business
Cybersecurity is Entering a New Era
Jim Guinn, EY Americas Cybersecurity Leader, shares how companies must stay vigilant and navigate the evolving regulatory landscape. *Sponsored by EY
Load More